APAC Built In, Not Bolted On

Global oncology and rare disease programs increasingly require Asia Pacific (APAC) inclusion from day one. Yet many sponsors still treat the region as a late-stage enrollment solution, creating avoidable delays, governance challenges, and regulatory hurdles. 

This eBook explores why leading sponsors are integrating APAC into pivotal trial design from the outset and how a unified governance model can accelerate timelines, strengthen global execution, and support future submissions in China, Japan, and beyond.

Key Insights Featured in the eBook

• Designing global clinical trials with APAC built into the development strategy from day one. 

• Governance frameworks for managing complex multi-country execution without fragmenting quality or data systems.

• Country-specific regulatory and operational considerations across key APAC markets.

• Practical approaches to site selection, regulatory planning, and enrollment optimization.

• Lessons learned from global Phase 1-3 oncology studies that successfully leveraged APAC participation.